This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
How Are Biotech ETFs Reacting to These Q4 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Omicron Vaccines to Hit Market Soon? ETF Areas to Benefit
by Sanghamitra Saha
Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Top ETF Stories of November
by Sanghamitra Saha
The emergence of the Omicron variant of Covid-19 and inflationary pressure were key highlights of the broader market in November.
Moderna ETFs Rallying on COVID-19 Vaccine News to Combat Omicron
by Sweta Jaiswal, FRM
Moderna has been rallying amid concerns surrounding the omicron variant, which has led to possibilities of a rise in demand for COVID-19 vaccines and boosters.
ETF Areas to Gain/Lose on Fear of Omicron Strain of Coronavirus
by Sanghamitra Saha
The emergence of a new coronavirus strain, namely Omicron, has caused a massacre on Wall Street on Friday. These ETFs could gain/lose in the coming days if Omicron cases continue to rise.
Moderna ETFs to Rally on Positive COVID-19 Booster Shot News
by Sweta Jaiswal, FRM
Moderna is expected to gain approval for booster shots for its COVID-19 vaccine.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
How Are Biotech ETFs Reacting to These Q3 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Can Biotech ETFs Gain From Positive Booster Update?
by Sweta Jaiswal, FRM
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Take a Look at the Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News
by Sweta Jaiswal, FRM
Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.
Best ETF Areas for Placing Your Bets in September
by Sweta Jaiswal, FRM
Let's take a look at some ETF areas that can be good investment options for September.
5 Top-Ranked ETFs That Outperformed in August
by Sweta Jaiswal, FRM
Let's take a look at some top-ranked ETFs that outperformed Wall Street in August.
Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs
by Sweta Jaiswal, FRM
The biotech space has once again come under the spotlight as the FDA has granted the first full U.S. approval to Pfizer (PFE)/BioNTech's (BNTX) coronavirus vaccine.
Biotech ETFs to Benefit From Latest Booster Update
by Sweta Jaiswal, FRM
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.
Moderna ETFs to Shine Bright on Booster Update, New Study Data
by Sweta Jaiswal, FRM
Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.
How Are Biotech ETFs Reacting to These Q2 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
ETF Investing Areas to Consider for August
by Sweta Jaiswal, FRM
Let's take a look at some ETF areas that can be good investment options for August.
Sanofi to Buy mRNA Developer: ETFs in Focus
by Sanghamitra Saha
Sanofi has agreed to acquire U.S. biotech company Translate Bio to gain exposure in the mRNA vaccine space.
Delta Variant Surge Brings Biotech ETFs in Focus
by Sweta Jaiswal, FRM
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
Time for Pharma and Healthcare ETFs?
by Sanghamitra Saha
The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales
2 Sector ETFs Hovering Around All-Time Highs
by Sanghamitra Saha
The U.S. economic backdrop and investors' sentiments have remained mixed in recent weeks.
Moderna Soars on Inclusion to S&P 500: ETFs in Focus
by Sanghamitra Saha
Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.
Moderna ETFs to Rise on Positive COVID-19 Vaccine Updates
by Sweta Jaiswal, FRM
Moderna has once again come up with interesting updates about its COVID-19 vaccine.